Immunotherapy Combination in HER2-Positive Breast Cancer
Kevin Kalinsky, MD, MS, assistant professor of medicine at Columbia University, discusses the results from a trial in HER2-positive breast cancer that was presented at the 2017 San Antonio Breast Cancer Symposium. The study looked at the use of trastuzumab (Herceptin) in combination with a checkpoint inhibitor in patients that were either PD-L1-positive or negative.
Kevin Kalinsky, MD, MS, assistant professor of medicine at Columbia University, discusses the results from a trial in HER2-positive breast cancer that was presented at the 2017 San Antonio Breast Cancer Symposium. The study looked at the use of trastuzumab (Herceptin) in combination with a checkpoint inhibitor in patients that were either PD-L1-positive or negative.
In patients that were PD-L1 positive, there was a significant difference in overall survival compared to PD-L1-negative patients. Kalinsky says that this poses the question of whether there is a small amount of patients that really respond to immunotherapy in this population.
Kalinsky also noted that it was interesting to see higher rates of stromal tumor-infiltrating lymphocytes in the PD-L1-positive cohort, where these lymphocytes seemed to be able to dichotomize those that would respond.
Elacestrant-Abemaciclib Combo Shows Promise for Breast Cancer
September 19th 2024The ELECTRA trial found that the combination of elacestrant and abemaciclib was well-tolerated and showed promising clinical activity in patients with ER-positive, HER2-negative metastatic breast cancer who had previously received endocrine therapy and another CDK4/6 inhibitor.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
POSITIVE Trial Shows Breastfeeding is Possible During Endocrine Therapy Break in HR+ Breast Cancer
Published: September 18th 2024 | Updated: September 16th 2024Follow-up results from the POSITIVE trial showed that breastfeeding is achievable for patients with HR-positive breast cancer who conceived during a break from endocrine therapy.
Read More
